Type stringclasses 2
values | Section_id stringclasses 4
values | Primary_id stringlengths 11 11 | Secondary_id stringlengths 0 11 | Statement stringlengths 34 385 | Label stringclasses 2
values | Primary_evidence_index listlengths 1 65 | Secondary_evidence_index listlengths 0 73 | Primary_ct stringlengths 1.11k 16.3k | Secondary_ct stringlengths 101 16.3k | __index_level_0__ stringlengths 36 36 |
|---|---|---|---|---|---|---|---|---|---|---|
Single | Eligibility | NCT00411788 | If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks, until today, she will be eligible for the primary trial next Tuesday. | Contradiction | [
18,
33
] | [] | {'Clinical Trial ID': 'NCT00411788', 'Intervention': ['INTERVENTION 1: ', ' Sirolimus and Trastuzumab', ' Patients received oral sirolimus 6 mg daily in combination with weekly trastuzumab administered intravenously with a loading dose of 4 mg/kg followed by 2 mg/kg weekly in a 28-day cycle. A subsequent amendment al... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0e8d1b4f-d6f6-455a-a7e3-07f67a8fbcc8 | |
Comparison | Intervention | NCT00382785 | NCT00784849 | Neither the primary trial or the secondary trial use Low Dose Magnesium Oxide, Biopsies or Mometasone in their intervention. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00382785', 'Intervention': ['INTERVENTION 1: ', ' Moderated Group', ' one 12-week online support group led by a professional healthcare provider', 'INTERVENTION 2: ', ' Non-facilitated (Peer-led)', ' 12-week online support in a peer-led format'], 'Eligibility': ['Inclusion Criteria: Clinic... | {'Clinical Trial ID': 'NCT00784849', 'Intervention': ['INTERVENTION 1: ', ' Sentinel Lymph Node Biopsy With Radiolabeled Methylene Blue', ' One arm diagnostic using 1 mCi of 125-I Methylene blue dye to find sentinel lymph nodes'], 'Eligibility': ['Inclusion Criteria:', ' Stage 0,I, II breast cancer', ' Clinical nod... | 9a346aac-46c2-4a50-8f3a-309b3b7bc295 |
Comparison | Adverse Events | NCT02132949 | NCT01111825 | Between both of the patient cohorts of the primary trial and the secondary trial there was only a single patient with a deficiency of granulocytes in the blood. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29
] | {'Clinical Trial ID': 'NCT02132949', 'Intervention': ['INTERVENTION 1: ', ' Cohort A: ddAC, Paclitaxel, Pertuzumab, Trastuzumab', ' Participants received neoadjuvant treatment with dose-dense doxorubicin and cyclophosphamide (ddAC), with administration of doxorubicin 60 milligrams per square meter (mg/m^2) intravenou... | {'Clinical Trial ID': 'NCT01111825', 'Intervention': ['INTERVENTION 1: ', ' Phase 2 Triple -ve', ' Phase 2, Triple - Negative cohort', 'INTERVENTION 2: ', ' Phase 2 HER2+', ' Phase 2, HER2 - Amplified (HER2-Positive) cohort'], 'Eligibility': ['Inclusion Criteria:', ' Phase I HER2-amplified Cohort', ' HER2 overexp... | 949d79e0-95db-47a2-802a-6280c0255923 |
Comparison | Adverse Events | NCT01325207 | NCT02429427 | Patients participating in the primary trial and the secondary trial experienced serious eye disorders. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | {'Clinical Trial ID': 'NCT01325207', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1 - Trastuzumab 10mg IT 2/Week', ' Intrathecal Trastuzumab 10 mg IT will be administered in Cohort 1 of dose escalation.', ' Trastuzumab: Trastuzumab will be administered twice per week for 4 weeks, then once per week for 4 weeks, and... | {'Clinical Trial ID': 'NCT02429427', 'Intervention': ['INTERVENTION 1: ', ' Celecoxib', ' Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.', ' Celecoxib: Patients will receive 400mg of Celecoxib o... | 6e080a1e-a03e-4547-a7c4-c9d5a80de977 |
Single | Eligibility | NCT01730729 | Patients with severe malabsorption disorders are ineligible for the primary trial, unless they are able to receive intravenous (IV) alimentation. | Contradiction | [
24,
31,
30
] | [] | {'Clinical Trial ID': 'NCT01730729', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Cabergoline)', ' Patients receive cabergoline oral (PO) twice weekly for weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.', ' cabergoline: Given orally'], 'Eligibility': ['Inc... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 63218fb2-3f5b-4738-bea8-11fbbc560949 | |
Single | Intervention | NCT01953003 | Patients receiving intervention 1 of the primary trial, will be administered medication orally and intraveinously. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [] | {'Clinical Trial ID': 'NCT01953003', 'Intervention': ['INTERVENTION 1: ', ' Arm A : iv Vinflunine Plus Capecitabine', ' Vinflunine dose 280 mg/m² on day 1 of each cycle every 3 weeks, Capecitabine 825 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest.', ' vi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d7fa4f81-e108-491f-9b08-c147a33863e8 | |
Single | Results | NCT00849472 | Two dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00849472', 'Intervention': ['INTERVENTION 1: ', ' AC, Followed by Weekly Paclitaxel and Concurrent Pazopanib', ' Participants were treated with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for 4 cycles. This was... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f24afb09-ea65-457f-9f9b-0db3cc3101ac | |
Single | Adverse Events | NCT00403130 | There were no cases of Leukopenia, Epitasis or Arrhythmia observed in patients participating in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00403130', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab + Gemcitabine + Paclitaxel', ' Gemcitabine 1000 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles', ' Paclitaxel 80 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles', ' Bevacizumab 10 mg/kg by IV infusion, days 1 ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3cd79df2-e6dd-41dd-b819-4d993b5f7aed | |
Single | Eligibility | NCT00090857 | Candidates for the primary trial must have a bone density scan 1 month prior to study entry, if the results from this are more than 2 standard deviations below normal, the study physician can still decide to let them participate. | Entailment | [
7,
8
] | [] | {'Clinical Trial ID': 'NCT00090857', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' Participants in this arm received 2.5 mg of letrozole per day for a duration of 12 months; followed by an optional 4 years. Treatment continued in the absence of unacceptable toxicity or diagnosis of invasive breast cancer, duct... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d2d6f646-5881-42a2-b965-0c6f79e89463 | |
Single | Results | NCT00022672 | There were no patients in either cohort of the primary trial with a PFS exceeding one year. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT00022672', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + Anastrozole', ' Trastuzumab 4 mg/kg loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole every day for 24 Months in the Main phase and in the Ex... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 428d5165-560b-4783-8c4b-5fd3a3289cab | |
Comparison | Intervention | NCT02536794 | NCT00712985 | the primary trial and the secondary trial both administer Zometa to their patients through IV, although in different doses. | Contradiction | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT02536794', 'Intervention': ['INTERVENTION 1: ', ' Treatment (MEDI4736, Tremelimumab)', ' Patients receive anti-B7H1 monoclonal antibody MEDI4736 IV over 1 hour and tremelimumab IV over 1 hour on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or una... | {'Clinical Trial ID': 'NCT00712985', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid 5 mg IV', ' Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time dose. Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone destruction (NTx & CTx).'], 'Eligibility': ['Inclusion ... | 6e7df2e4-11b3-4183-aefc-760f85809515 |
Single | Results | NCT01439711 | One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) over 3 months. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01439711', 'Intervention': ['INTERVENTION 1: ', ' Letrozole + MRI', ' Protocol Therapy will consist of 6 months of letrozole, administered orally at a dose of 2.5 mg/day. Patients will have a bilateral MRI for disease evaluation at months 3 and 6.'], 'Eligibility': ['Eligibility Criteria:', ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 45e6b4b6-ca31-4318-936e-5b27cbca47a2 | |
Single | Eligibility | NCT00458237 | Patient who have recently undergone External beam radiation therapy are eligible for the primary trial. | Entailment | [
0,
6
] | [] | {'Clinical Trial ID': 'NCT00458237', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Everolimus (Dose Level 1) and Trastuzumab', ' Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 5 mg by mouth daily on days 1-21. Participants are... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 22a6d10e-55c5-4a8c-8010-3e8252bcb279 | |
Comparison | Intervention | NCT00593346 | NCT00902330 | the primary trial treament last for a shorter period of time than the secondary trial treatment, but is administered much more often. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT00593346', 'Intervention': ['INTERVENTION 1: ', ' Accelerated Partial Breast Brachytherapy', ' Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.', ' Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given o... | {'Clinical Trial ID': 'NCT00902330', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Cranial Microcurrent Electrical Stimulation [CES])', ' Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes. The CES unit is pr... | 7fd1ae1e-bfdb-4c37-aaea-ed97663758e3 |
Single | Adverse Events | NCT03078751 | Cohort 1 of the primary trial reported one case of AML. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [] | {'Clinical Trial ID': 'NCT03078751', 'Intervention': ['INTERVENTION 1: ', ' Ribociclib + Adjuvant Endocrine Therapy (ET)', ' Patients in this arm took Ribociclib in combination with standard adjuvant endocrine therapy. ET was one of these 4: Letrozole, Anastrozole, Exemestane, Tamoxifen (Tamoxifen no longer permitted... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 50d119f6-a657-4619-918e-7617ac57f052 | |
Single | Eligibility | NCT01009918 | There are no racial criteria for entry into the primary trial, however there are gender criteria. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20
] | [] | {'Clinical Trial ID': 'NCT01009918', 'Intervention': ['INTERVENTION 1: ', ' Arm I Lisinopril', ' Patients receive oral lisinopril once daily.', ' lisinopril: Given orally', 'INTERVENTION 2: ', ' Arm II Coreg CR®', ' Patients receive oral Coreg CR® once daily.', ' Coreg CR®: Given orally'], 'Eligibility': ['INCLUS... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e436827b-10db-4179-bf8f-07786ee6145b | |
Single | Eligibility | NCT00631852 | Patients with hemophilia are excluded from the primary trial. | Entailment | [
12,
19
] | [] | {'Clinical Trial ID': 'NCT00631852', 'Intervention': ['INTERVENTION 1: ', ' American Ginseng Root', ' four, 250mg tablets daily 5-14 days prior to surgery', ' American Ginseng root: four, 250mg tablets daily 5-14 days prior to surgery'], 'Eligibility': ['Inclusion Criteria:', ' Patients with cytologically confirmed... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | fcc6708a-b0fc-4215-a45f-02b1e0e2d30a | |
Comparison | Eligibility | NCT00944047 | NCT00228943 | Patients with tumors underexpressing HER2 are excluded from the primary trial, but may be included in the secondary trial. | Entailment | [
0,
4
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT00944047', 'Intervention': ['INTERVENTION 1: ', ' Intervention Arm', ' Nab-paclitaxel, trastuzumab, doxorubicin, cyclophosphamide, Growth Factor Support, Surgery', ' nab-paclitaxel: 100 MG/M2 IV over 30 minutes once a week for 12 weeks', ' trastuzumab: 4 MG loading dose followed by 2 MG/KG... | {'Clinical Trial ID': 'NCT00228943', 'Intervention': ['INTERVENTION 1: ', ' Full Strength Acute Tryptophan Depletion', '[Not Specified]', 'INTERVENTION 2: ', ' Half-Strength Tryptophan Depletion - Control', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' At least 18 years of age', ' Willing and able to... | d63706f1-4fb8-488d-8f86-c1a19df341d4 |
Single | Eligibility | NCT02694029 | Candidates for the primary trial are expected to be capable of holding their breath for half a minute. | Entailment | [
0,
6
] | [] | {'Clinical Trial ID': 'NCT02694029', 'Intervention': ['INTERVENTION 1: ', ' Radiation With ABC', ' Active Breathing Coordinator to assist radiation therapy. This group will be administered 14 fractions with ABC-assisted DIBH', ' Active Breathing Coordinator (ABC): The ABC system has a digital spirometer that records... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ab357056-67a7-4227-966d-8c96eb1640fd | |
Single | Eligibility | NCT00635050 | Patients with Breast cancers that have estrogen receptors are excluded from the primary trial. | Entailment | [
0,
2
] | [] | {'Clinical Trial ID': 'NCT00635050', 'Intervention': ['INTERVENTION 1: ', ' Doxil, Paclitaxel, Cyclophosphamide + Avastin', ' Two stage phase II single arm trial to evaluate the pathologic complete response rate to sequential dose dense chemotherapy using Doxil, paclitaxel and cyclophosphamide with concurrent Avastin... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0359eef3-6339-485e-95bc-0cb6fa7bcd12 | |
Comparison | Intervention | NCT00791037 | NCT00606931 | the primary trial and the secondary trial do not use the same route of administration for their interventions. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00791037', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Vaccine Therapy+ex Vivo-expanded T Cells)', ' Patients receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. Beginning 2 weeks later, patients undergo leukapheresis to isolate and collect peri... | {'Clinical Trial ID': 'NCT00606931', 'Intervention': ['INTERVENTION 1: ', ' PET Guided Biopsy', ' No comparison group. All enrolled participants were expected to undergo PET guided biopsy.'], 'Eligibility': ['Inclusion Criteria:', ' Individuals aged 25 years or older', ' Individuals who have at least one breast ima... | 57ef3c6c-b4e1-4302-b423-aa9faca21200 |
Single | Adverse Events | NCT00091442 | There were more cases of Febrile neutropenia than eukopenia observed in the primary trial, but less cases of Febrile neutropenia than Neutropenia. | Entailment | [
0,
2,
3,
4
] | [] | {'Clinical Trial ID': 'NCT00091442', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel', ' Docetaxel monotherapy: Docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.', 'INTERVENTION 2: ', ' DOXIL+Docetaxel', ' DOXIL and docetaxel combination: DOXIL 30 mg/m2 so... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 29d5779b-c228-4b82-9ca8-075beadae879 | |
Single | Intervention | NCT00591864 | the primary trial patients receive Trametinib, Akt Inhibitor GSK2141795 PO QD on days 1-28, up to a maximum of 8 cycles. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00591864', 'Intervention': ['INTERVENTION 1: ', ' Study Participants', ' There are no arms or subgroups in this study.'], 'Eligibility': ['Inclusion Criteria:', ' This study will include a population of women aged 25 or older who are scheduled for a breast MRI examination at MAYO CLINIC ROC... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4e124d90-68d7-40bd-a8b1-27cb49d64c64 | |
Single | Intervention | NCT00291694 | the route of administration for both interventions in the primary trial is a topical skin cream. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00291694', 'Intervention': ['INTERVENTION 1: ', ' Celecoxib', ' Randomized to receive celecoxib daily for 12 months', 'INTERVENTION 2: ', ' Placebo', ' Randomized to receive placebo daily for 12 months'], 'Eligibility': ['Inclusion Criteria:', ' women who have a high risk of breast cancer... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0a9a7f5b-eb32-4a11-86e3-5a9a6377eea3 | |
Single | Adverse Events | NCT01674062 | One patient in the primary trial was observed suffering from Enteritis. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT01674062', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab + Trastuzumab (Cohorts 1 and 2)', ' Females with HER2-positive metastatic breast cancer received dual-agent treatment with pertuzumab and trastuzumab. Recruitment for Cohorts 1 and 2 was conducted separately; however, the same regi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f4c7dae5-012f-4f05-b5ba-da072fe1359c | |
Comparison | Intervention | NCT01067976 | NCT00941330 | Unlike the secondary trial, the primary trial does not provide a duration of cycles or any dosages in the intervention section. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | {'Clinical Trial ID': 'NCT01067976', 'Intervention': ['INTERVENTION 1: ', ' CMRM vs UMRM', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' Recent histologically proven diagnosis of breast cancer after having obtained X-Ray Mammography (XRM) of both breasts (according to American College of Radiology [ACR... | {'Clinical Trial ID': 'NCT00941330', 'Intervention': ['INTERVENTION 1: ', ' A: Exemestane', ' ARM A: Patients will be treated with exemestane.', ' Exemestane: 25 mg daily by mouth for 6 to 12 months.', 'INTERVENTION 2: ', ' B: Docetaxel and Cytoxan', ' ARM B: Patients will be treated with docetaxel and cytoxan.', ... | 927bbb75-37da-4b75-9483-252d31a0fd98 |
Single | Adverse Events | NCT01610284 | 1 patient in the primary trial had a cardiac related adverse event. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT01610284', 'Intervention': ['INTERVENTION 1: ', ' BKM120 100mg + Fulvestrant', ' BKM120 100 mg per day and fulvestrant given until progression or as described in the protocol.', 'INTERVENTION 2: ', ' Placebo + Fulvestrant', ' BKM120 matching placebo daily and fulvestrant given until progre... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 80a5cdbc-0721-41b6-af1a-28e3f46557ce | |
Comparison | Adverse Events | NCT00217672 | NCT00110084 | the primary trial had three times the occurence rate of fistula enterovesical as the secondary trial. | Contradiction | [
0,
4
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | {'Clinical Trial ID': 'NCT00217672', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel + Bevacizumab', ' docetaxel: 75 mg/m2 IV q3 weeks. Bevacizumab: 15mg/kg IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.'], 'Eligibility': [... | {'Clinical Trial ID': 'NCT00110084', 'Intervention': ['INTERVENTION 1: ', ' Nab-paclitaxel/Gemcitabine', ' Nab (nanoparticle albumin-bound)-Paclitaxel (125mg/m^2)(IV over 30 min) (days 1 and 8) on 21 day cycle and gemcitabine (1000 mg/m^2)(IV over 30 min) (days 1 and 8) on 21 day cycle'], 'Eligibility': ['DISEASE CHA... | af710d36-8062-4412-8d11-1c57a14b5e5a |
Single | Adverse Events | NCT00717405 | There were several patients who contracted Pneumonia in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00717405', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab + Trastuzumab', ' Neoadjuvant treatment (Cycles 1-8, 3-week cycle): Participants received 15 mg/kg IV bevacizumab q3w for 8 cycles, 4 cycles of 500 mg/m^2 IV 5-fluorouracil, 100 mg/m^2 IV epirubicin, and 500 mg/m^2 IV cyclophospha... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c91c7dc1-17b7-4475-9aec-38999a18a306 | |
Comparison | Adverse Events | NCT00243503 | NCT00448279 | the primary trial and the secondary trial observed a different number of adverse events in their patients. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT00243503', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + Sunitinib', ' Trastuzumab was administered intravenously (i.v) weekly (loading 4 mg/kg followed by weekly 2 mg/kg) or every 3 weeks (loading 8 mg/kg followed by 6 mg/kg thrice weekly). Sunitinib began with 37.5 mg by oral capsul... | {'Clinical Trial ID': 'NCT00448279', 'Intervention': ['INTERVENTION 1: ', ' Chemotherapy Alone', " Participants received chemotherapy until disease progression, unacceptable toxicity, or death; the schedule and dose at the investigator's discretion and per local prescribing guidelines and standard center practice. Al... | 5357ce66-7f7b-4ffd-926c-f6116f5a2e20 |
Single | Eligibility | NCT00399529 | Women with chronic obstructive pulmonary disease that do not require systemic corticosteroids, are eligible for the primary trial. | Entailment | [
8
] | [] | {'Clinical Trial ID': 'NCT00399529', 'Intervention': ['INTERVENTION 1: ', ' Allo GM-CSF-secreting Vaccine, Trastuzumab, Cyclophosphamide', ' Allogeneic GM-CSF-secreting breast cancer vaccine : the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3c7ecca8-5397-41f5-b72b-84217bf3acd2 | |
Comparison | Adverse Events | NCT00615901 | NCT00829166 | the primary trial recorded more seizures than the secondary trial, despite having less than one tenth the number of patients in its total cohort. | Entailment | [
0,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | {'Clinical Trial ID': 'NCT00615901', 'Intervention': ['INTERVENTION 1: ', ' Cohort A (CMF at 14 Day Intervals)', ' This is a pilot study using 8 cycles of CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2), at 14 day intervals supported by PEG-filgrastim for a cohort of 38 patients. A... | {'Clinical Trial ID': 'NCT00829166', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine', ' Participants received trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination.', ... | 2c53e14a-719c-4994-9090-73f9bddb60ba |
Single | Results | NCT00089999 | In total more participants in the primary trial had no tumor Response, than partial response, and only 3 patients had a complete response. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT00089999', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib 1500 mg QD', ' Participants received lapatinib 1500 mg orally QD. Treatment was continued for 12 weeks or until disease progression or withdrawal from treatment for another reason. After Week 12, participants with clinical benefit h... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7c1b03bc-d299-4ee8-b9ee-3d253f3fc33a | |
Comparison | Intervention | NCT00820222 | NCT01819233 | the secondary trial and the primary trial interventions both require subjects to follow caloric restricted diets or gluten free diets, while completing food diaries. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT00820222', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib Plus Capecitabine', ' Participants received a daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same time every day, either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast. Participants also r... | {'Clinical Trial ID': 'NCT01819233', 'Intervention': ['INTERVENTION 1: ', ' Behavioral Dietary Intervention', ' Beginning 2-4 weeks after completion of lumpectomy, patients receive food diaries to complete for 7-10 days. Dietary counselors then give patients guidelines for dietary modifications to reduce caloric inta... | bfb617c8-51ae-4ab2-be05-6346daad5437 |
Single | Eligibility | NCT00404066 | Abnormal LVEF, Pregnancy or lactating automatically eliminates patients from participating in the primary trial, unless treated with herbal medicines. | Contradiction | [
17,
22,
28,
29
] | [] | {'Clinical Trial ID': 'NCT00404066', 'Intervention': ['INTERVENTION 1: ', ' Neoadjuvant Chemotherapy', ' Doxorubicin (Adriamycin) + cyclophosphamide (Cytoxan) with pegfilgrastim or filgrastim growth factor support every 2 weeks for 4 cycles, followed by docetaxel + lapatinib for four 21-day cycles, followed by surger... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | dcc5c3b0-848b-4ef4-afe6-e9c9933e33af | |
Comparison | Adverse Events | NCT00455533 | NCT00767520 | Throughout both the secondary trial and the primary trial there was only one case of pregnancy, in cohort 1 of the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | {'Clinical Trial ID': 'NCT00455533', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone', ' ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)', 'INTERVENTION 2: ', ' Paclitaxel', ' paclitaxel 80 mg/m^2 administered IV every week for 12 weeks'], 'Eligibility': ... | {'Clinical Trial ID': 'NCT00767520', 'Intervention': ['INTERVENTION 1: ', ' Exemestane + Dasatinib', ' Oral dose of exemestane 25 mg + dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity', 'INTERVENTION 2: ', ' Exemestane + Placebo', ' Oral dose of exemestane 25 mg + placebo 100 mg, onc... | 18fcd396-cb03-4e80-bb2d-ee03c12ba32a |
Single | Results | NCT00038103 | There is no significant difference in the proportions of Subjects With Clinical Benefit in the Exemestane + Celecoxib cohort and in the Exemestane alone cohort of the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00038103', 'Intervention': ['INTERVENTION 1: ', ' Exemestane (Exemestane Alone)', ' oral dose exemestane taken with food (25 mg tablet once daily)', 'INTERVENTION 2: ', ' Combination (Exemestane + Celecoxib)', ' oral doses to be taken with food (25 mg tablet exemestane once daily; celecoxi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 694c5820-ebb6-4271-8685-a0b51c637f7f | |
Single | Results | NCT00662025 | on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00662025', 'Intervention': ['INTERVENTION 1: ', ' SUNITINIB+CAPECITABINE', ' Sunitinib was administered orally from Day 1 at the starting dose of 37.5 mg/day on a continuous daily dosing schedule in 21-day cycles. Capecitabine was administered orally from Days 1 to 14 every 21 days at a star... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b87abb47-13b6-4dbe-9cfd-e63075b676aa | |
Single | Eligibility | NCT00754845 | Patients who received over 5 years of anastrozole therapy, completed under a year ago, are eligible for the primary trial. | Contradiction | [
2,
3
] | [] | {'Clinical Trial ID': 'NCT00754845', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' Patients receive oral letrozole once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.', ' letrozole: Given orally', 'INTERVENTION 2: ', ' Placebo', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | eb025223-1b4a-4df7-a85e-2eeeb62a6bf5 | |
Single | Adverse Events | NCT02149524 | None of the adverse events which occurred in the primary trial were not GI related. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT02149524', 'Intervention': ['INTERVENTION 1: ', ' Herceptin (Trastuzumab)', ' Intravenous administration', ' Herceptin (trastuzuamb): Intravenous administration', 'INTERVENTION 2: ', ' SB3 (Proposed Trastuzumab Biosimilar)', ' Intravenous administration', ' SB3 (proposed trastuzumab bios... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 23df2cc2-6aae-4251-a8a7-e2f5a65f176a | |
Comparison | Eligibility | NCT00418028 | NCT00293540 | Samantha has recently received a liver transplant, and is taking the combined oral contraceptive pill, she is not eligible for the primary trial, but is eligible for the secondary trial. | Contradiction | [
7,
10
] | [
3,
4
] | {'Clinical Trial ID': 'NCT00418028', 'Intervention': ['INTERVENTION 1: ', ' Arm A (Cint)', ' Capecitabine will be administered orally at a dose of 1250 mg/m2 twice-daily (in the morning and in the evening, the equivalent of a total daily dose of 2500 mg/m2) for 14 days, in 3 week cycles with a resting period of 7 day... | {'Clinical Trial ID': 'NCT00293540', 'Intervention': ['INTERVENTION 1: ', ' A Mid-luteal Surgery', '[Not Specified]', 'INTERVENTION 2: ', ' B Mid-follicular Surgery', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' Estrogen receptor or progesterone receptor positive breast cancer', ' Premenopausal with... | 1bd51c93-d7a8-4da4-825d-ada625033c34 |
Single | Results | NCT01827787 | The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the HR+/HER2- cohort. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT01827787', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1: HR+/HER2-', ' Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle', ' Participants remained on single agent eribulin until disease progression or withdrawal for other reasons.', 'INT... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 58c58b68-fc9a-438c-8a85-9233dde714c9 | |
Single | Adverse Events | NCT00965523 | The most common adverse events in the primary trial where Infection and Stomatitis. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00965523', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate', ' Eribulin mesylate 1.4 mg/m^2 intravenous infusion given over 2 to 5 minutes on Day 1 and 8 every 21 days.'], 'Eligibility': ['Inclusion criteria:', ' Female patients with histologically or cytologically confirmed breast... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 843778c6-a320-49a1-93a0-5dc6239b822a | |
Single | Adverse Events | NCT00080301 | There were 2 more cases of Gastrointestinal Haemorrhage in cohort 2 of the primary trial, than in cohort 1. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT00080301', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone + Capecitabine', ' Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each 21-day cycle, plus oral capecitabine 1000 mg/m2 twice a day (BID) x 14 days', 'INTERVENTION 2: ', ' Capecitabine', ' Cap... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a5486f80-69e5-4a5a-8435-f82f39cddf85 | |
Single | Adverse Events | NCT00171314 | There are four types of adverse events in the primary trial, for which no occurences are recorded. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00171314', 'Intervention': ['INTERVENTION 1: ', ' Upfront Zoledronic Acid', ' Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.', 'INTERVENTION 2: ', ' De... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c2c60b25-f255-48ba-bcb7-2bcd2de4315d | |
Comparison | Intervention | NCT00068601 | NCT01684215 | the primary trial and the secondary trial do not employ the same route of administration for their interventions. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00068601', 'Intervention': ['INTERVENTION 1: ', ' Standard Chemotherapy', ' Patients receive cyclophosphamide-containing chemotherapy alone.', ' cyclophosphamide: Part of planned chemotherapy regimen', 'INTERVENTION 2: ', ' Chemotherapy Plus Goserelin', ' Patients receive goserelin subcut... | {'Clinical Trial ID': 'NCT01684215', 'Intervention': ['INTERVENTION 1: ', ' PD-0332991 100 mg: Dose Escalation Cohort', ' In Phase 1-Part 1, participants received single oral dose of PD-0332991 100 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 100 mg capsule orally once daily co... | a8167a90-8ccf-4024-a4cc-8c1b047fd548 |
Single | Intervention | NCT00106002 | the primary trial participants are treated with 600 mg of Pemetrexed orally twice a month until complete response or disease progression. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00106002', 'Intervention': ['INTERVENTION 1: ', ' Pemetrexed', ' 600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression'], 'Eligibility': ['Inclusion Criteria:', ' Must have been diagnosed with either advanced or metastatic breast cancer.', ' Chemotherapy... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | bdca0fa1-a3fa-4dcf-8f58-15d130dbfa75 | |
Comparison | Intervention | NCT01067976 | NCT00941330 | Unlike the secondary trial, the primary trial only provides the duration of cycles and drug doses in the intervention section. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | {'Clinical Trial ID': 'NCT01067976', 'Intervention': ['INTERVENTION 1: ', ' CMRM vs UMRM', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' Recent histologically proven diagnosis of breast cancer after having obtained X-Ray Mammography (XRM) of both breasts (according to American College of Radiology [ACR... | {'Clinical Trial ID': 'NCT00941330', 'Intervention': ['INTERVENTION 1: ', ' A: Exemestane', ' ARM A: Patients will be treated with exemestane.', ' Exemestane: 25 mg daily by mouth for 6 to 12 months.', 'INTERVENTION 2: ', ' B: Docetaxel and Cytoxan', ' ARM B: Patients will be treated with docetaxel and cytoxan.', ... | 277f5d17-36cc-44c5-9b94-7e052f2bdb2c |
Single | Adverse Events | NCT01492101 | There less than 1% of either cohort of the primary trial was effect by Pancytopenia, but just over 5% of cohort 1 patients suffered from Coagulopathy. | Contradiction | [
0,
4,
5,
11,
15
] | [] | {'Clinical Trial ID': 'NCT01492101', 'Intervention': ['INTERVENTION 1: ', ' NKTR-102', ' NKTR-102: 145 mg/m2 NKTR-102 will be delivered q21day as a 90 minute intravenous (IV) infusion on day 1 of each treatment cycle.', 'INTERVENTION 2: ', " Physician's Treatment of Choice", " Treatment of Physician's Choice (TPC):... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | fcb195de-2143-44d8-8c46-136104554e2d | |
Single | Eligibility | NCT00317720 | Patients must have at least 3 prior treatments with trastuzumab to be eligible for the primary trial. | Contradiction | [
0,
2
] | [] | {'Clinical Trial ID': 'NCT00317720', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + RAD001', ' Trastuzumab loading dose is 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle. RAD001 10 mg PO (by mouth) daily.'], 'Eligibility': ['Inclusion Criteria:', ' History of biopsy-proven HER-2-overexpressing... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 70337af9-3d4a-44bc-bbfa-0d97ea88553c | |
Single | Eligibility | NCT00334542 | A Female patients with a mastectomy would be excluded from the primary trial. | Contradiction | [
6
] | [] | {'Clinical Trial ID': 'NCT00334542', 'Intervention': ['INTERVENTION 1: ', ' Simvastatin', ' Simvastatin 40 mg for 24-28 weeks'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' History of histologically confirmed breast cancer, meeting 1 of the following staging criteria:', ' Ductal carcinoma in situ', ' Stage I-III... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9cf89221-5801-4709-a098-de763b6e702e | |
Single | Eligibility | NCT01031446 | Sarah has been experiencing epileptic seizures from a brain tumor. This will not prevent her from participating in the primary trial. | Contradiction | [
5
] | [] | {'Clinical Trial ID': 'NCT01031446', 'Intervention': ['INTERVENTION 1: ', ' RAD001 and Cisplatin and Paclitazel', ' Cisplatin intravenously (IV) weekly for 3 weeks, then 1 week of rest; paclitaxel IV weekly for 3 weeks, then 1 week of rest. Everolimus (RAD001) po daily. One cycle = 4 weeks'], 'Eligibility': ['DISEASE... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f89883ea-dd60-4d5f-9354-13fbca2aeec8 | |
Comparison | Adverse Events | NCT01301729 | NCT02129556 | Only 1 respiratory adverse event was recorded across the duration of both the secondary trial and the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | {'Clinical Trial ID': 'NCT01301729', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' Participants with metastatic breast cancer received a loading dose of 4 milligrams per kilograms (mg/kg) of trastuzumab intravenously (IV) followed by 2 mg/kg of trastuzumab IV once a week along with docetaxel 100 milligrams p... | {'Clinical Trial ID': 'NCT02129556', 'Intervention': ['INTERVENTION 1: ', ' Phase Ib 2 mg/kg', ' HER2-positive, PD-L1 expressing, unresectable loco-regional or metastatic breast carcinoma that progressed on prior trastuzumab-based therapy', 'INTERVENTION 2: ', ' Phase Ib 10 mg/kg', ' HER2-positive, PD-L1 expressing... | a289f67c-ff56-44a9-b3da-152fb0d20271 |
Single | Eligibility | NCT02635737 | Patients with ICDs may be eligible for the primary trial. | Contradiction | [
6,
7
] | [] | {'Clinical Trial ID': 'NCT02635737', 'Intervention': ['INTERVENTION 1: ', ' Sentimark Device Placement', ' Sentimark device placed in women having mastectomy surgery', ' Sentimark: Placement of a metallic clip with paramagnetic properties for tumour localisation'], 'Eligibility': ['Inclusion Criteria:', ' Participa... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 10ed1242-c6ab-4ad0-b93c-4738857f543a | |
Single | Eligibility | NCT02692755 | Asian, white british and white irish women are eligible for the primary trial, as long as they do not have uncontrolled or symptomatic brain metastases. | Contradiction | [
0,
1,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT02692755', 'Intervention': ['INTERVENTION 1: ', ' Palbociclib + Letrozole or Fulvestrant', ' Palbociclib + Letrozole or Fulvestrant: Palbociclib x 21 days with a 7 day rest plus 2.5 mg Letrozole QD (no break) or Fulvestrant 500mg IM every 2 weeks for 3 doses and then every 4 weeks until prog... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 683b9885-4027-4108-b37e-61255611538a | |
Single | Intervention | NCT00600340 | Cohorts 1 of the primary trial recieves Bevacizumab at a higher frequency and dose than cohort 2. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00600340', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab Plus Paclitaxel', ' Bevacizumab 10 mg/kg intravenous (i.v.), days 1 and 15, every 4 weeks, Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks', 'INTERVENTION 2: ', ' Bevacizumab Plus Capecitabine', ' Bevacizumab 15 mg/kg i.v.,... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a47e048a-56aa-49e0-9903-563f53797b6e | |
Comparison | Eligibility | NCT00356148 | NCT01856543 | Women of any age can participate in the primary trial and the secondary trial. | Contradiction | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00356148', 'Intervention': ['INTERVENTION 1: ', ' Prophylaxis Group', ' patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis', 'INTERVENTION 2: ', ' No Prophylaxis Group', ' Patients who are BMI over 25 and not receive antibiotic prophylaxis'], 'Eligibility': ['Inclu... | {'Clinical Trial ID': 'NCT01856543', 'Intervention': ['INTERVENTION 1: ', ' Eucerin', ' Patient education regarding amount to be applied (amount depending on body habitus) and area of treatment field will be reinforced by the R.N. prior to the first radiation treatment. Part of patient education may involve applicati... | 690de5e2-3d7f-407e-8eb9-783adf58841b |
Comparison | Adverse Events | NCT01234337 | NCT00217672 | More than 2 cases of Anaphylaxis occurred in either the primary trial or the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT01234337', 'Intervention': ['INTERVENTION 1: ', ' Sorafenib (Nexavar, BAY43-9006) + Capecitabine', ' Sorafenib tablets were administered orally continuously at a total daily dose of 600 mg (200 mg in the morning, 400 mg in the evening) in a 3-week cycle. Capecitabine was administered orally ... | {'Clinical Trial ID': 'NCT00217672', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel + Bevacizumab', ' docetaxel: 75 mg/m2 IV q3 weeks. Bevacizumab: 15mg/kg IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.'], 'Eligibility': [... | f5477a02-dde7-44c8-80b5-2cdb9fa66f23 |
Single | Eligibility | NCT03511378 | Patients must have a life expectancy over a year to participate in the primary trial. | Contradiction | [
0,
8
] | [] | {'Clinical Trial ID': 'NCT03511378', 'Intervention': ['INTERVENTION 1: ', " Lupin's Pegfilgrastim", ' 6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.', " Lupin's Pegfilgrastim: Administration of Pegfilgrastim", 'INTERVENTION 2: ', ' Neulasta®', ' 6 mg, subcutaneous injection ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | dc184dcb-a22d-4cac-bee1-6c182692e522 | |
Comparison | Intervention | NCT03076190 | NCT03196635 | Molecular Breast Imaging is not applied in either the primary trial or the secondary trial interventions. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT03076190', 'Intervention': ['INTERVENTION 1: ', ' Active Control Group', ' Health Education Active Control Group', 'INTERVENTION 2: ', ' My Surgical Success Treatment Group', ' My Surgical Success Intervention Group'], 'Eligibility': ['Inclusion Criteria:', ' Age 18+', ' Scheduled for br... | {'Clinical Trial ID': 'NCT03196635', 'Intervention': ['INTERVENTION 1: ', ' All Study Participants, PA Compression Image Sets', ' All image sets (30 patient-assisted compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers.', 'INTERVENTION 2: ', ' All Study Partic... | 4dfbdeba-cae0-48b2-a38d-07338512904e |
Comparison | Results | NCT01097460 | NCT01009918 | Every patient in the primary trial and the secondary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT01097460', 'Intervention': ['INTERVENTION 1: ', ' MM-111 + Herceptin', ' MM-111 will be combined with Herceptin', ' MM-111 and Herceptin: For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV'], 'Eligibility': ['Inclusion Criteria:', ' Patie... | {'Clinical Trial ID': 'NCT01009918', 'Intervention': ['INTERVENTION 1: ', ' Arm I Lisinopril', ' Patients receive oral lisinopril once daily.', ' lisinopril: Given orally', 'INTERVENTION 2: ', ' Arm II Coreg CR®', ' Patients receive oral Coreg CR® once daily.', ' Coreg CR®: Given orally'], 'Eligibility': ['INCLUS... | 62489179-bb30-4b96-a904-ea907dd05e23 |
Single | Eligibility | NCT01011946 | All patients in the primary trial must have a bilateral breast mammography prior to study entry. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [] | {'Clinical Trial ID': 'NCT01011946', 'Intervention': ['INTERVENTION 1: ', ' Positron Emission Mammography', ' Positron Emission Mammography: Patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ul... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 45891239-bb78-4f83-8306-8edceb8247fe | |
Comparison | Intervention | NCT00258349 | NCT01328249 | Cohort 1 of the primary trial does not receive any Eribulin Mesylate or Vorinostat, whereas both cohorts in the secondary trial receive some of both. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00258349', 'Intervention': ['INTERVENTION 1: ', ' Vorinostat +Trastuzumab', ' Trastuzumab: 6 mg/kg once on Day 1, infused over 90 minutes, every 3 weeks;', ' Vorinostat 200 mg of SAHA orally twice a day, daily for 14 days out of a 21-day cycle'], 'Eligibility': ['Inclusion Criteria:', ' No... | {'Clinical Trial ID': 'NCT01328249', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1: Eribulin Mesylate With Filgrastim as Needed', " Participants initially received doxorubicin (60 mg/m^2) plus cyclophosphamide (600 mg/m^2) intravenously (IV) on Day 1, of every 14-day cycle for 4 cycles. Eribulin mesylate was admini... | 9ec1e3f0-64a2-4629-aee8-cdb516fd27f3 |
Single | Eligibility | NCT00371254 | Patients must have eceptorsestrogen receptor (ER) -, progesterone receptor (PR) - and human epidermal growth factor receptor 2 (HER2) - non metastatic breast cancer, aswell as not having Dysphagia. | Contradiction | [
0,
2,
8,
12
] | [] | {'Clinical Trial ID': 'NCT00371254', 'Intervention': ['INTERVENTION 1: ', ' Dasatinib 100 mg BID', ' Participants were administered an oral dose of 100 mg dasatinib tablet twice daily for a total daily dose (TDD) of 200 mg. Study treatment continued for as long as it was tolerated, or until progressive disease (PD), ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 91f23b55-38b6-41c4-af30-baa15e989aa7 | |
Single | Results | NCT00374322 | the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were twice as likely to achieve DFS at 5 years than placebo patients. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19
] | [] | {'Clinical Trial ID': 'NCT00374322', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib 1500 mg', ' Participants received lapatinib 1500 milligrams (mg) orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study trea... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7eea6ac2-ef9a-4c3e-b14d-eb9671dab89d | |
Comparison | Eligibility | NCT02650193 | NCT00656669 | Patients with Class III obesity cannot be included in the primary trial, but can be entered into the secondary trial, as long as they do not have uncontrolled Hypertension. | Entailment | [
0,
15
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18
] | {'Clinical Trial ID': 'NCT02650193', 'Intervention': ['INTERVENTION 1: ', ' Cycle 0: HSP-130 3mg', ' Participants who had not received background chemotherapy treatment in the study were administered a single dose of 3 mg of HSP-130 SC at Day 1 of Cycle 0. Participants were followed approximately 30 days after last d... | {'Clinical Trial ID': 'NCT00656669', 'Intervention': ['INTERVENTION 1: ', ' Sunitinib Monotherapy', ' Patients who completed the Sunitinib monotherapy segment'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have histologically-confirmed adenocarcinoma of the breast with operable or inoperable stage 1c (pri... | a2d489d5-3677-43ef-b03a-33d571c0c3b2 |
Comparison | Adverse Events | NCT00423917 | NCT00082641 | the primary trial and the secondary trial both report cases of confusion in their patient cohorts. | Entailment | [
0,
5
] | [
0,
7,
8,
15
] | {'Clinical Trial ID': 'NCT00423917', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant + Bevacizumab', ' Patients receive Fulvestrant 250 mg intramuscularly every 28 days and Bevacizumab 10mg/kg intravenously with a rate-regulating device on days 1 and 15. Loading dose of fulvestrant for the first cycle will consist... | {'Clinical Trial ID': 'NCT00082641', 'Intervention': ['INTERVENTION 1: ', ' Arm I', ' Patients receive vaccination comprising p53-infected autologous dendritic cells subcutaneously (SC) 1 week after completion of doxorubicin and cyclophosphamide, 1 week after completion of paclitaxel (or after surgery for patients wi... | 943ff737-4edd-4dbd-a3c9-213e3e0234d8 |
Single | Eligibility | NCT01042938 | Only patients capable of understanding english are eligible for the primary trial. | Entailment | [
0,
11
] | [] | {'Clinical Trial ID': 'NCT01042938', 'Intervention': ['INTERVENTION 1: ', ' Curcumin C3 Complex', ' Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT) (~4-7 weeks).', 'INTERVENTION 2: ', ' Placebo', ' Patients take 2.0 grams placebo (f... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | be50c45f-ec51-40c8-904f-ffc200d39d9d | |
Comparison | Intervention | NCT04030104 | NCT02525718 | Intervention 1 for the secondary trial and the primary trial either include no treatment at all, or a placebo. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT04030104', 'Intervention': ['INTERVENTION 1: ', ' IUS Alone', 'IUS alone imaging', 'INTERVENTION 2: ', ' Imagio (IUS+OA)', 'IUS+OA imaging'], 'Eligibility': ['Inclusion Criteria:', ' One analyzable mass per patient: BI-RADS 3 and 4a, 4b, 4c and 5 masses as declared by clinical site investig... | {'Clinical Trial ID': 'NCT02525718', 'Intervention': ['INTERVENTION 1: ', ' Placebo', ' Subjects will be randomly selected to receive saline (placebo), administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery.', ' Saline: If randomized to this arm, subjects will rece... | f53c8212-6da8-470f-a392-1bb037ed90e8 |
Single | Results | NCT02622074 | There were twice as many patients with DLT in cohort 2 of the primary trial than in cohort 1. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [] | {'Clinical Trial ID': 'NCT02622074', 'Intervention': ['INTERVENTION 1: ', ' Cohort A: KNp / KAC', ' Participants received pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7b7e6e8b-aa62-4fcd-af1e-c243995243d1 | |
Single | Results | NCT02162719 | the primary trial does not investigate the effects of its intervention on patient tpCR. | Entailment | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT02162719', 'Intervention': ['INTERVENTION 1: ', ' Ipatasertib and Paclitaxel', ' Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, in... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 74a53536-bb9d-4c64-9280-679d7b660cdd | |
Single | Adverse Events | NCT00728949 | There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least three cases. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [] | {'Clinical Trial ID': 'NCT00728949', 'Intervention': ['INTERVENTION 1: ', ' IMC-A12 (Cixutumumab) + Antiestrogen Therapy', ' Participants will receive intravenous IMC-A12 10 mg/kg over 1 hour every 2 weeks, as well as the same dose and schedule of the last antiestrogen therapy to which their disease became refractory... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6b35c306-a699-44f2-8606-a58d58fc18f3 | |
Comparison | Intervention | NCT00784849 | NCT02104895 | Breast breast irradiation is used in some form for both cohorts of the secondary trial, but not at all in the primary trial. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT00784849', 'Intervention': ['INTERVENTION 1: ', ' Sentinel Lymph Node Biopsy With Radiolabeled Methylene Blue', ' One arm diagnostic using 1 mCi of 125-I Methylene blue dye to find sentinel lymph nodes'], 'Eligibility': ['Inclusion Criteria:', ' Stage 0,I, II breast cancer', ' Clinical nod... | {'Clinical Trial ID': 'NCT02104895', 'Intervention': ['INTERVENTION 1: ', ' Whole Breast Irradiation (WBI)', ' Conventional whole breast irradiation (WBI)', ' Whole breast irradiation (WBI): Conventional whole breast irradiation (WBI)', 'INTERVENTION 2: ', ' Partial Breast Irradiation (APBI)', ' Accelerated partia... | 62f50fe5-a83d-4f07-9dc7-8f495254d398 |
Single | Eligibility | NCT00121134 | the primary trial requires participants to have a primary tumor > 5cm in longest dimension. | Contradiction | [
0,
3
] | [] | {'Clinical Trial ID': 'NCT00121134', 'Intervention': ['INTERVENTION 1: ', ' Group A- Bevacizumab Alone', ' Bevacizumab 15 mg/kg every 3 wks for 1 year', 'INTERVENTION 2: ', ' Group B-Bevacizumab+Cyclophosphamide+Methotrexate', ' Bevacizumab 15 mg/kg every 3 weeks for 1 year +Cyclophosphamide 50 mg orally daily for ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | edcae553-8a0a-45d2-a0fa-4db68608ef03 | |
Single | Intervention | NCT00748553 | Patients in the primary trial receive 5 doses of Azacitidine (Vidaza) every month and 3 doses of Nab-paclitaxel (Abraxane) per month. | Entailment | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT00748553', 'Intervention': ['INTERVENTION 1: ', ' Phase 1', ' Azacitidine (Vidaza): 50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle', ' Nab-paclitaxel (Abraxane): 100mg/m2 weekly for 3 weeks of each 4-week cycle'], 'Eligibility': ['Inclusion Criteria:', ' For phase I, a... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a1b3667f-bfa5-426a-975a-20ed350c12c0 | |
Single | Results | NCT02915744 | The difference in median, maximum and minimum Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one month. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT02915744', 'Intervention': ['INTERVENTION 1: ', ' NKTR-102', ' In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle.', 'INTERVENTION 2: ', " Treatment of Physician's Choice (TPC)",... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 903617fa-7c40-45ac-a03c-498f51879408 | |
Single | Adverse Events | NCT00171314 | There are four types of adverse events in the primary trial, for which one occurence is recorded. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00171314', 'Intervention': ['INTERVENTION 1: ', ' Upfront Zoledronic Acid', ' Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.', 'INTERVENTION 2: ', ' De... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9436e18a-a055-41c3-980f-bf451b4da7ee | |
Comparison | Adverse Events | NCT01201265 | NCT00932373 | 1 patient in the primary trial was affected by Sepsis, and several were affected in the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29
] | {'Clinical Trial ID': 'NCT01201265', 'Intervention': ['INTERVENTION 1: ', ' All Participants', ' Participants received a combination therapy of bevacizumab 15 milligram per kilogram (mg/kg) intravenous every 3 weeks with carboplatin recommended dose (area under curve [AUC]= 2) along with gemcitabine 1000 mg/ metre sq... | {'Clinical Trial ID': 'NCT00932373', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab-MCC-DM1 0.3 mg/kg Every 3 Weeks', ' Trastuzumab-MCC-DM1 0.3 mg/kg administered intravenously (IV) once every 3 weeks', 'INTERVENTION 2: ', ' Trastuzumab-MCC-DM1 0.6 mg/kg Every 3 Weeks', ' Trastuzumab-MCC-DM1 0.6 mg/kg administe... | f57403d9-7278-481e-bcb9-066bf31b6158 |
Comparison | Adverse Events | NCT00688909 | NCT00129376 | Patients in the primary trial and the secondary trial did not suffer from any of the same adverse events. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT00688909', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' Participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks.'], 'Eligibility': ['Inclusion Criteria:', ' Postmenopausal women with HR+ early stage breast cancer at the time of i... | {'Clinical Trial ID': 'NCT00129376', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin + Cyclophosphamide Followed Docetaxel', ' Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles (days 1, 22, 43 and 64). Three weeks late... | ec601f6b-6ce3-4df7-b7b3-fbde1a241e93 |
Comparison | Intervention | NCT00291135 | NCT00291694 | The duration of treatment in the primary trial is half as long as in the secondary trial, but twice as frequent. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00291135', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' Letrozole, 2.5 mg daily for six months'], 'Eligibility': ['Inclusion Criteria:', ' evidence of hyperplasia with/without atypia upon random periareolar fine needle aspiration of breast', ' on hormone replacement therapy', ' po... | {'Clinical Trial ID': 'NCT00291694', 'Intervention': ['INTERVENTION 1: ', ' Celecoxib', ' Randomized to receive celecoxib daily for 12 months', 'INTERVENTION 2: ', ' Placebo', ' Randomized to receive placebo daily for 12 months'], 'Eligibility': ['Inclusion Criteria:', ' women who have a high risk of breast cancer... | 0f0e5a8e-3972-46c2-84dd-7436e82a9787 |
Single | Results | NCT00191152 | The longest Time to Disease Progression the primary trial was over 21 days in the Docetaxel Plus Capecitabine group. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | [] | {'Clinical Trial ID': 'NCT00191152', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine Plus Docetaxel', ' gemcitabine 1000 milligrams per meter squared (mg/m2) intravenous, days 1 and 8 every 21 days plus docetaxel 75 mg/m2, intravenous, day 1 every 21 days.', ' Treatment continues until progression of disease at w... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 420e4977-ce75-4fab-99e0-3e7db837d521 | |
Single | Results | NCT00096356 | the primary trial results indicate that CoQ10 reduces the PFS of breast cancer patients compared to a placebo by about 8% | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00096356', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 - CoQ10 & Vitamin E', ' CoQ10 100mg capsule combined with Vitamin E 100 IU taken orally three times per day.', 'INTERVENTION 2: ', ' Arm 2 - Placebo & Vitamin E', ' Placebo-Vitamin E 100 mg/day in 3 doses'], 'Eligibility': ['Inclusion... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d07b4a30-e74f-468a-8420-7ade791d372d | |
Comparison | Adverse Events | NCT02536339 | NCT00371345 | At least one type of respiratory illness was observed in patients from both the primary trial and the secondary trial. | Entailment | [
0,
3
] | [
0,
11
] | {'Clinical Trial ID': 'NCT02536339', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab + Trastuzumab', ' Participants with CNS metastases secondary to HER2-positive MBC, who had disease progression in the brain following previous treatment with radiotherapy (whole-brain radiation therapy or stereotactic radiosurgery)... | {'Clinical Trial ID': 'NCT00371345', 'Intervention': ['INTERVENTION 1: ', ' Her2/Neu-amplified Tumor, 70 mg Twice Daily (BID) Dasatinib', ' Participants with a Human epidermal growth factor (Her2/neu)-amplified tumor type (defined as 3+ by immunohistochemistry [IHC] or positive by fluorescent or chromogenic in situ h... | 412b2743-8f76-494a-af97-f7bf9541a890 |
Comparison | Eligibility | NCT00631852 | NCT00193037 | Patients may be forced to take part in the secondary trial and the primary trial, even against their consent, as long as it is in their best interests. | Contradiction | [
0,
8
] | [
0,
9
] | {'Clinical Trial ID': 'NCT00631852', 'Intervention': ['INTERVENTION 1: ', ' American Ginseng Root', ' four, 250mg tablets daily 5-14 days prior to surgery', ' American Ginseng root: four, 250mg tablets daily 5-14 days prior to surgery'], 'Eligibility': ['Inclusion Criteria:', ' Patients with cytologically confirmed... | {'Clinical Trial ID': 'NCT00193037', 'Intervention': ['INTERVENTION 1: ', ' Arm A -Liposomal Doxorubicin Then Docetaxel', ' Liposomal doxorubicin (Arm A)', ' Liposomal doxorubicin 40 mg/m2 IV day 1 over one hour, repeated q 28 days thru peripheral vein or central venous access. This will define one cycle.', ' Patie... | fd43feb6-4a55-4de6-b21d-25ff723b0959 |
Comparison | Adverse Events | NCT01256567 | NCT01926886 | The most common adverse event in the primary trial was Febrile neutropenia (14.29%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%). | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01256567', 'Intervention': ['INTERVENTION 1: ', ' Ramucirumab and Docetaxel Combination', ' Docetaxel: Docetaxel administered by intravenous infusion at a dose of 75 milligrams per square meter (mg/m^2) every 3 weeks.', ' Ramucirumab: Ramucirumab administered as an intravenous infusion at a... | {'Clinical Trial ID': 'NCT01926886', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' Participants received trastuzumab IV infusion at initial loading dose of 8 mg/kg BW for q3w regimen as a part of neo adjuvant treatment before entering in the study and then recommended maintenance dose of 6 mg/kg BW q3w for t... | e1fa68ac-42b4-4223-a362-a89c43562e06 |
Comparison | Adverse Events | NCT03165955 | NCT00912340 | 2 patients in the primary trial suffer from DVT, 0 in the secondary trial. | Contradiction | [
8
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | {'Clinical Trial ID': 'NCT03165955', 'Intervention': ['INTERVENTION 1: ', ' Oraxol (Oral Paclitaxel Plus HM30181)', ' Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.'], 'Eligibility': ['Inclusion Criteria:', ' Signed written informed consent', ' Women 18 years of age on day of consent', ' Breast cancer ... | {'Clinical Trial ID': 'NCT00912340', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' Patients receive trastuzumab IV over 30 minutes once every 3 weeks and continue to receive their most recent hormone therapy. Patients achieving disease progression receive everolimus PO daily in combination with trastuzumab a... | 6f5570c0-4114-47ee-9611-b2e4be91cf9a |
Single | Results | NCT01224678 | Intervention 2 of the primary trial resulted in a lower percentage change in tumor diameter than intervention 1. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01224678', 'Intervention': ['INTERVENTION 1: ', ' Placebo', ' Patients receive oral placebo once daily for 12 months.', 'INTERVENTION 2: ', ' Vitamin D', ' Patients receive oral vitamin D (2000 IU) once daily for 12 months.'], 'Eligibility': ['Premenopausal women 55 years of age or younger... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 13b4a3c5-cf6e-4f65-9f94-be927c3ce5ef | |
Single | Results | NCT02581839 | All participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) >= 16 weeks. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT02581839', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate', ' The recommended starting dose of eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. An MRI will be completed at week 1, week 12 and every 12 weeks after cycle... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6495c223-f7d9-459f-8c57-66a2caac5ee4 | |
Comparison | Intervention | NCT01216319 | NCT03346161 | the secondary trial and the primary trial are evaluating interventions associated with breast reconstruction for patients that have had mastectomies. | Entailment | [
0,
1,
2
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01216319', 'Intervention': ['INTERVENTION 1: ', ' Nipple Reconstruction Cylinder', ' Nipple reconstruction: Biodesign® Nipple Reconstruction Cylinder'], 'Eligibility': ['Inclusion Criteria:', ' Patient presents with a history of breast cancer, having previously completed either uni- or bi-l... | {'Clinical Trial ID': 'NCT03346161', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: BREASTChoice (Decision Tool)', " Investigators recruited patients scheduled for a plastic/reconstruction consult. Investigators identified patients who completed a mastectomy, or were scheduled for one, and considering reconstruction, ... | eb61fee2-30fc-42f9-80bd-4d73d6af592c |
Single | Results | NCT00091832 | Both cohorts of the primary trial in a negative (mean) Percent Change From Baseline of Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr). | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00091832', 'Intervention': ['INTERVENTION 1: ', ' Bisphosphonate IV Q4W', ' Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion', 'INTERVENTION 2: ', ' Denosumab 30 mg Q4W', ' Denosumab 30 mg by subcutaneous injection every 4 weeks (Q4W)'], 'Eligibility': ['Inclusion Crit... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 79c698bf-a756-4a73-8075-38c3c5eb7a04 | |
Single | Eligibility | NCT00571987 | Breast implants and Diffuse microcalcifications will not disqualify a patient from entry to the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26
] | [] | {'Clinical Trial ID': 'NCT00571987', 'Intervention': ['INTERVENTION 1: ', ' Margin Status', ' AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe): Generator is connected to a single use probe. Probe is inserted into the lumpectomy cavity and heated... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f7be0a6e-6c63-473e-af00-df009f3d7d46 | |
Comparison | Intervention | NCT01376349 | NCT01912612 | Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects, of the two cohorts in the secondary trial only the cohort without pain recieves Duloxetine 30 mg daily. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT01376349', 'Intervention': ['INTERVENTION 1: ', ' Arm I Low Dose DHEA', ' Participants apply a low dose (3.25 mg) of vaginal prasterone (dehydroepiandrosterone [DHEA]) gel once daily (QD), at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to ... | {'Clinical Trial ID': 'NCT01912612', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 (Patients With Pain)', ' Duloxetine 30 mg daily x 1 week, then 60 mg daily x 4 weeks, then 30 mg daily x 2 weeks.', ' Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days, then 60 mg duloxetine orally for 28 days, then ... | 6f686de9-f110-4be0-9cd8-1ceb0ce6f073 |
Single | Eligibility | NCT01004744 | Patients must have a confirmed pregnancy by positive Hcg test, if they are to take part in the primary trial. | Contradiction | [
2
] | [] | {'Clinical Trial ID': 'NCT01004744', 'Intervention': ['INTERVENTION 1: ', ' Presurgical Oral Anastrozole', ' 1mg daily for two weeks in the interval between diagnostic breast biopsy and definitive breast surgery.', ' Anastrozole: 1mg PO daily for two weeks prior to scheduled surgery'], 'Eligibility': ['Inclusion Cri... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2c602b4d-c8a5-4606-8e3a-a87ee7bbc480 | |
Single | Results | NCT02463032 | There was less than a 5% difference in the Percentage of Participants With Objective Response in the GTx-024 9 mg and GTx-024 18 mg group in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT02463032', 'Intervention': ['INTERVENTION 1: ', ' GTx-024 9 mg', ' Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg', ' GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.', 'INTERVENTION 2: ', ' GT... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ffa913b7-9875-458e-8a28-476f9e788bb0 | |
Single | Adverse Events | NCT00193206 | the primary trial records a total of 7 different types of infections. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00193206', 'Intervention': ['INTERVENTION 1: ', ' Intervention', ' Systemic Therapy', ' ABI-007 : ABI-007 175 mg/m2 D1 q 14 days x 6 cycles', ' Epirubicin : Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles', ' Gemcitabine : Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles'], 'Eligibility': ['... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5a4018ea-5d00-4d44-bfa3-a1dfb341b9e5 | |
Comparison | Intervention | NCT03456427 | NCT02685566 | There are no details concerning the duration or frequency of administration in the intervention sections of the primary trial and the secondary trial | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT03456427', 'Intervention': ['INTERVENTION 1: ', ' All Study Participants: Patient Assisted Compression', ' All subjects will undergo standard of care imaging on one breast. The other breast will be imaged using Patient-Assisted Compression (PAC), followed by Technologist-controlled (TC) Comp... | {'Clinical Trial ID': 'NCT02685566', 'Intervention': ['INTERVENTION 1: ', ' FFDM Plus DBT', ' Breast Images with FFDM and DBT FFDM Plus DBT: FujiFilm Aspire Cristalle System.', ' This endpoint will be evaluated qualitatively. The Pass Criteria require adequate performance in non-cancer cases (recall rate) and in can... | d8e47fe7-be41-4f74-881b-a80cd3a1e95f |
Comparison | Intervention | NCT00236899 | NCT01153672 | the primary trial and the secondary trial do not use any of the same drugs in their interventions. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT00236899', 'Intervention': ['INTERVENTION 1: ', ' Treatment Schedule (Weekly)', ' Arm C, Docetaxel and Gemcitabine (Weekly):', ' Docetaxel: 30 mg/m², 30-60 min IV infusion on Days 1, 8, and 15 to be given 30 minutes prior to Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs... | {'Clinical Trial ID': 'NCT01153672', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Enzyme Inhibitor Therapy, AI Sensitization Therapy)', ' Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD, letrozole PO QD, OR exemestane PO QD for 6 weeks. Courses repeat every 8 wee... | e77e15a3-d851-4174-80c3-7b5156e7f987 |
Single | Results | NCT01806259 | In total Over 85% patient in the primary trial achieve Recurrence-free Survival after 3 years. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | [] | {'Clinical Trial ID': 'NCT01806259', 'Intervention': ['INTERVENTION 1: ', ' Ketorolac 30 mg', ' Active drug to be compared with placebo', 'Ketorolac 30 mg IV', 'INTERVENTION 2: ', ' NaCl 0.9% 3mL', 'Ketorolac 30 mg IV'], 'Eligibility': ['Inclusion Criteria:', ' Written informed Consent age : 18-85 years weight: 50-... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c003dd08-af3b-44cc-b31c-6fbdadfa1d83 | |
Comparison | Adverse Events | NCT00455533 | NCT00767520 | Throughout both the secondary trial and the primary trial there was only one case of sudden and unexpected death, in cohort 1 of the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | {'Clinical Trial ID': 'NCT00455533', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone', ' ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)', 'INTERVENTION 2: ', ' Paclitaxel', ' paclitaxel 80 mg/m^2 administered IV every week for 12 weeks'], 'Eligibility': ... | {'Clinical Trial ID': 'NCT00767520', 'Intervention': ['INTERVENTION 1: ', ' Exemestane + Dasatinib', ' Oral dose of exemestane 25 mg + dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity', 'INTERVENTION 2: ', ' Exemestane + Placebo', ' Oral dose of exemestane 25 mg + placebo 100 mg, onc... | 8ddf49c7-316e-4c7c-b2dd-423182a37612 |
Single | Adverse Events | NCT01498458 | For all adverse event types in the primary trial, at least one case was recorded. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT01498458', 'Intervention': ['INTERVENTION 1: ', ' Pazopanib Plus Capecitabine', ' A maximal tolerated dose (MTD) could not be established. The study was stopped after 8 patients.'], 'Eligibility': ['Inclusion Criteria:', ' Written informed consent for all study procedures according to local... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d9e41be5-1e37-4dff-b51a-166576f351d0 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.